A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock Hennigsdorf/Berlin, November 13, 2025 – 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) today announced the ...

Cancer treatments can exert cardiotoxic effects, but screening and monitoring can detect and minimize cancer therapy-related ...

The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

Unlike the general population, patients on maintenance hemodialysis have both traditional and nontraditional risk factors that put them at high cardiovascular risk, despite use of standard lipid and ...

The path forward to prioritizing women’s health and well-being must be laid by Canadians whose voices propel political, social and economic change around the world.

Carondelet St. Mary's Hospital has successfully completed its first implantation of the Barostim™ Baroreflex Activation ...

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

Among patients with heart failure and reduced ejection fraction (HFrEF), those taking a “polypill” combination of three medications typically prescribed for heart failure, once daily for six months, ...